IDH mutation
Showing 1 - 25 of 2,728
Correlation Between SPECT/CT and IDH Mutation in Brain Glioma
Not yet recruiting
- Brain Glioma
- (no location specified)
Oct 23, 2022
Single Photon Emission Computed Tomography/Computed Tomography
Not yet recruiting
- Brain Glioma
- SPECT with pentavalent 99mTc DMSA
- (no location specified)
Oct 23, 2022
How Habitats Created by MRI Can Predict IDH Mutation Status and
Recruiting
- High-grade Glioma
-
Chongqing, Chongqing, ChinaDepartment of Radiology, Daping Hospital of Army Medical Univers
Aug 1, 2022
Glioma, IDH Mutation, Astrocytoma Trial in Philadelphia (Retifanlimab, All-trans retinoic acid)
Not yet recruiting
- Glioma
- +3 more
- Retifanlimab
- All-trans retinoic acid
-
Philadelphia, PennsylvaniaUniversity of Pennsylvania
Jul 22, 2022
Recurrent IDH1/2 Mutated Glioma Trial in Paris (Azacitidine)
Recruiting
- Recurrent IDH1/2 Mutated Glioma
-
Paris, FrancePitie Salpetriere Hospital
Aug 29, 2022
IDH Mutation, IDH1 Mutation, IDH2 Gene Mutation Trial in Chicago (Ivosidenib, Enasidenib, Fedratinib)
Recruiting
- IDH Mutation
- +4 more
- Ivosidenib
- +2 more
-
Chicago, IllinoisUniversity of Chicago Medical Center
Nov 12, 2021
Space Occupying Lesions of the Brain
Recruiting
- Brain Tumor
- +2 more
- MR-scans using a 3T Prisma and a 7T Terra scanner (Siemens, Erlangen Germany)
-
Bern, SwitzerlandInstitute for Diagnostic and Interventional Neuroradiology, Univ
Jan 26, 2023
Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic Trial (Ivosidenib)
Not yet recruiting
- Cholangiocarcinoma Non-resectable
- Cholangiocarcinoma Metastatic
- (no location specified)
Oct 10, 2023
Low-grade Glioma, IDH2 Gene Mutation, Recurrent Glioma Trial in Boston (Niraparib, Resection/Treatment with Niraparib)
Recruiting
- Low-grade Glioma
- +4 more
- Niraparib
- Resection/Treatment with Niraparib
-
Boston, MassachusettsMassachusetts General Hospital
Oct 19, 2022
Cholangiocarcinoma With IDH1 Mutation, Solid Tumors With IDH1 Mutation Trial in Beijing (AB-218 capsule)
Not yet recruiting
- Cholangiocarcinoma With IDH1 Mutation
- Solid Tumors With IDH1 Mutation
- AB-218 capsule
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital, Chinese Academy of Medica
Apr 2, 2023
Glioma, Cholangiocarcinoma, Solid Tumor Trial in Toronto (Olaparib, Durvalumab)
Recruiting
- Glioma
- +3 more
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Nov 29, 2021
Glioma, IDH Mutation Trial (BAY 2402234)
Withdrawn
- Glioma
- IDH Mutation
- BAY 2402234
- (no location specified)
Dec 17, 2021
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia
Recruiting
- Acute Myeloid Leukemia
- +6 more
- Biospecimen Collection
- +2 more
-
Orange, California
- +9 more
Jan 27, 2023
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1
Not yet recruiting
- Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
- Ivosidenib 500mg
- Placebo
- (no location specified)
Nov 7, 2023
IDH1-mutant Cholangiocarcinoma Trial (Ivosidenib, Recommended Combination Dose (RCD) of ivosidenib, Nivolumab)
Not yet recruiting
- IDH1-mutant Cholangiocarcinoma
- Ivosidenib
- +3 more
- (no location specified)
Jun 29, 2023
Acute Myeloid Leukemia, Relapsed Cancer, Refractory Cancer Trial in Edmonton, Toronto (Enasidenib, Venetoclax)
Active, not recruiting
- Acute Myeloid Leukemia
- +3 more
-
Edmonton, Alberta, Canada
- +1 more
Jan 31, 2023
Accelerated/Blast-phase Myeloproliferative Tumor, Chronic-phase Myelofibrosis, IDH2 Mutation Trial in Canada, United States
Recruiting
- Accelerated/Blast-phase Myeloproliferative Neoplasm
- +2 more
-
Scottsdale, Arizona
- +10 more
May 9, 2022
Leukemia, Leukemia, Myeloid, Monocytic Leukemia Trial in Palo Alto (Enasidenib mesylat dose escalation)
Recruiting
- Leukemia
- +2 more
- Enasidenib mesylat dose escalation
-
Palo Alto, CaliforniaStanford Cancer Institute
May 12, 2022
Advanced Solid Tumor, IDH1 Mutation, Glioma Trial in Pittsburgh (ivosidenib and nivolumab)
Recruiting
- Advanced Solid Tumor
- +2 more
- ivosidenib and nivolumab
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Mar 14, 2022
Isocitrate Dehydrogenase Gene Mutation Trial in Spain, United States (HMPL-306)
Recruiting
- Isocitrate Dehydrogenase Gene Mutation
-
Santa Monica, California
- +8 more
Feb 22, 2022
Recurrent Glioma, Recurrent Glioblastoma, Poly ADP Ribose Polymerase (PARP) Inhibitor Trial in Hong Kong (Talazoparib)
Recruiting
- Recurrent Glioma
- +4 more
-
Hong Kong, Hong KongDepartment of Clinical Oncology
Aug 19, 2021
Molecular Pathology Research Project of Glioma
Completed
- Glioma, Malignant
- Detection of IDH and TERT mutation
-
Shanghai, Jingan District, ChinaHuashan Hospital
Mar 9, 2022
Non Invasive IDentification of Gliomas With IDH1 Mutation
Completed
- Non Invasive Diagnosis of Glioma
-
Paris, Sélectionner..., FranceGH Pitié-Salpêtrière, 47 Bd de l'Hopital,
Aug 25, 2021
IDH1 Mutation Myeloid Tumors Trial in Baltimore, Boston, Columbus (Ivosidenib)
Active, not recruiting
- IDH1 Mutation Myeloid Neoplasms
-
Baltimore, Maryland
- +3 more
Oct 25, 2021